Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.63 |
| ▸ | RELA | Q04206 | 2/20 | 0.63 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.44 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Blxa4 SCHEMBL29563817 | 1.00 | FPR2 (0.63) | FPR2NFKB1NFKB2RELALTB4R2 | |
| SCHEMBL19008213 | 0.90 | FPR2 (0.50) | FPR2NFKB1NFKB2RELAMAPT | |
| SCHEMBL590254 | 0.87 | NFKB1 (0.65) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL22956003 | 0.87 | NFKB1 (0.65) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL590256 | 0.87 | NFKB1 (0.65) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL29564346 | 0.87 | NFKB1 (0.65) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL590253 | 0.87 | NFKB1 (0.65) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL29935444 | 0.87 | NFKB1 (0.65) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL590255 | 0.87 | NFKB1 (0.65) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL18532102 | 0.85 | NFKB1 (0.44) | FPR2NFKB1NFKB2RELALTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165069-A1 | METHODS FOR TREATING DYSGEUSIA AND OTHER LINGERING SYMPTOMS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTIONADN CORONAVIRUS DISEASE 2019 | NOCENDRA, INC | 2024-05-23 | — | — | US | claimed |
| US-11896571-B2 | Methods for increasing oral osteogenesis using lipoxin A4 (LXA4) and its analogs | FORSYTH DENTAL INFIRMARY FOR CHILDREN (US) | 2024-02-13 | — | — | US | claimed |
| US-20230355562-A1 | METHODS FOR STABILIZING ATHEROSCLEROTIC PLAQUES USING LIPOXINS, RESOLVINS, AND ANALOGS THEREOF | ADA FORSYTH INSTITUTE, INC. | 2023-11-09 | — | — | US | claimed |
| US-11439615-B2 | Lipoxin and lipoxin analogue mediated neuroprotection and treatments | UNIVERSITY HEALTH NETWORK (CA) | 2022-09-13 | — | — | US | claimed |
| WO-2022178249-A1 | METHOD FOR TREATING DYSGEUSIA AND OTHER SYMPTOMS ASSOCIATED WITH COVID-19 | NOCENDRDA, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| CN-114377138-A | Method for stabilizing atherosclerotic plaques using lipoxins, resolvins and analogs thereof | 福塞斯儿童牙科医院 | 2022-04-22 | — | — | CN | claimed |
| CN-107438366-B | Method for stabilizing atherosclerotic plaques using lipoxins, resolvins and analogs thereof | 福塞斯儿童牙科医院 | 2022-03-15 | — | — | CN | claimed |
| US-20260108486-A1 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | NOCENDRA INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12527760-B2 | Synthesis of pro-resolving analogs and compositions therefor | NOCENDRA INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2025068966-A2 | SYNERGISTIC DENTIFRICE (ORAL) COMPOSITION, FORMULATION AND PREPARATION METHOD AND APPLICATION THEREOF | RAI BALWANT (IN) | 2025-04-03 | — | — | WO | disclosed |
| EP-4486393-A2 | CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS | Thetis Pharmaceuticals LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119136842-A | Cyclodextrin complexes that specialize in resolution mediators | 西蒂斯制药有限责任公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-107438366-B | Method for stabilizing atherosclerotic plaques using lipoxins, resolvins and analogs thereof | 福塞斯儿童牙科医院 | 2022-03-15 | — | — | CN | disclosed |
| US-20220040136-A1 | TREATMENT OF VULVOVAGINAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-10 | — | — | US | disclosed |
| WO-2021021552-A1 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | NOCENDRA INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-8093417-B2 | Lipoxin analogs and methods for the treatment of periodontal disease | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093417-B2 | Lipoxin analogs and methods for the treatment of periodontal disease | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110064677-A1 | LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110064677-A1 | LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11439615-B2 | Lipoxin and lipoxin analogue mediated neuroprotection and treatments | ALOX15B, ALOX12, NLN | FPR2 524/4885NFKB1 1488/4885NFKB2 1471/4885 |
| US-20110064677-A1 | LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE | ALOX5, ALOX15B, ALOX12 | FPR2 38/4885NFKB1 343/4885NFKB2 450/4885 |
| US-11896571-B2 | Methods for increasing oral osteogenesis using lipoxin A4 (LXA4) and its analogs | LOXL4, LTA4H, BMP4 | FPR2 310/4885NFKB1 1316/4885NFKB2 1596/4885 |
| US-12527760-B2 | Synthesis of pro-resolving analogs and compositions therefor | ALOX15B, ALOX12, ALOX5 | FPR2 52/4885NFKB1 2338/4885NFKB2 2710/4885 |
| US-20230355562-A1 | METHODS FOR STABILIZING ATHEROSCLEROTIC PLAQUES USING LIPOXINS, RESOLVINS, AND ANALOGS THEREOF | ALOX15B, ALOX15, ALOX5 | FPR2 160/4885NFKB1 1222/4885NFKB2 2037/4885 |
| US-20260108486-A1 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | ALOX15B, ALOX12, ALOX15 | FPR2 32/4885NFKB1 3016/4885NFKB2 3399/4885 |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | ALOX15, ALOX12, PTGES | FPR2 39/4885NFKB1 660/4885NFKB2 388/4885 |
| US-20240165069-A1 | METHODS FOR TREATING DYSGEUSIA AND OTHER LINGERING SYMPTOMS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTIONADN CORONAVIRUS DISEASE 2019 | LTA4H, LTB4R2, LTB4R | FPR2 361/4885NFKB1 3461/4885NFKB2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.